Restricted accessCase reportFirst published online 2015-5
Transformation to Small Cell Lung Cancer as an Acquired Resistance Mechanism in EGFR -mutant Lung Adenocarcinoma: A Case Report of Complete Response to Etoposide and Cisplatin
First-line epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for patients with advanced non-small cell lung cancer who were selected on the basis of EGFR mutations have improved the progression-free survival with acceptable toxicity compared to standard chemotherapy. However, acquired resistance to EGFR-TKIs has been identified as an important clinical problem. Transformation to small cell lung cancer (SCLC) is a rare mechanism of resistance to EGFR-TKI therapy. We describe the case of a 61-year-old man who presented transformation from adenocarcinoma to SCLC as the manifestation of acquired resistance after EGFR-TKI treatment. He underwent chemotherapy with etoposide and cisplatin and achieved a complete response.
PaoW.MillerV.A.Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol.2005; 23(11): 2556–2568.
2.
MillerV.A.KrisM.G.ShahN.Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol.2004; 22(6): 1103–1109.
3.
GaoG.RenS.LiA.Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: a meta-analysis from six phase III randomized controlled trials. Int J Cancer.2012; 131(5): E822–E829.
4.
OxnardG.R.ArcilaM.E.ChmieleckiJ.LadanyiM.MillerV.A.PaoW.New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res.2011; 17(17): 5530–5537.
5.
ZakowskiM.F.LadanyiM.KrisM.G.; Memorial Sloan-Kettering Cancer Center Lung Cancer OncoGenome Group. EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med.2006; 355(2): 213–215.
6.
SequistL.V.YangJ.C.YamamotoN.Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol.2013; 31(27): 3327–3334.
7.
KobayashiS.BoggonT.J.DayaramT.EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med.2005; 352(8): 786–792.
8.
EngelmanJ.A.ZejnullahuK.MitsudomiT.MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science.2007; 316(5827): 1039–1043.
9.
YanoS.WangW.LiQ.Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res.2008; 68(22): 9479–9487.
10.
YamamotoC.BasakiY.KawaharaA.Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. Cancer Res.2010; 70(21): 8715–8725.
11.
SudaK.TomizawaK.FujiiM.Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol.2011; 6(7): 1152–1161.
12.
TatematsuA.ShimizuJ.MurakamiY.Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res.2008; 14(19): 6092–6096.
13.
SequistL.V.WaltmanB.A.Dias-SantagataD.Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transi Med.2011; 3(75): 75ra26.
14.
YuH.A.ArcilaM.E.RekhtmanN.Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res.2013; 19(8): 2240–2247.
15.
GazdarA.F.MinnaJ.D.Deregulated EGFR signaling during lung cancer progression: mutations, amplicons, and autocrine loops. Cancer Prev Res (Phila).2008; 1(3): 156–160.
16.
PolitiK.ZakowskiM.F.FanP.D.SchonfeldE.A.PaoW.VarmusH.E.Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev.2006; 20(11): 1496–1510.
17.
ChangY.KimS.Y.ChoiY.J.Neuroendocrine differentiation in acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitor. Tuberc Respir Dis (Seoul).2013; 75(3): 95–103.
18.
WatanabeS.SoneT.MatsuiT.Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma. Lung Cancer.2013; 82(2): 370–372.
